Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.

ABSTRACT:

Background

We report the results of a phase I/II, open-label, single-arm clinical trial to evaluate the safety and anti-human immunodeficiency virus type 1 (HIV-1) efficacy of an autologous dendritic cell (DC)-based HIV-1 vaccine loaded with autologous HIV-1-infected apoptotic cells.

Methods

Antiretroviral therapy (ART)-naive individuals were enrolled, and viremia was suppressed by ART prior to delivery of 4 doses of DC-based vaccine. Participants underwent treatment interruption 6 weeks after the third vaccine dose. The plasma HIV-1 RNA level 12 weeks after treatment interruption was compared to the pre-ART (ie, baseline) level.

Results

The vaccine was safe and well tolerated but did not prevent viral rebound during treatment interruption. Vaccination resulted in a m

SUBMITTER: Macatangay BJ 

PROVIDER: S-EPMC4813736 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature